Skip to main content
Livermore
Livermore
ZHEN

Akebia Therapeutics, Inc.

AKBA
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001517022

No open-market purchases or sales by Akebia Therapeutics, Inc. insiders were filed in the last 90 days; 170 institutions reported holding it in 13F filings for Q2 2026, worth $123.2M in total; no superinvestor holds it.

Q2 2024 vs. Q1 2024

How the institutions holding Akebia Therapeutics, Inc. changed between Q1 2024 and Q2 2024.

All holders in Q2 2024All holders in Q1 2024

13F holders of AKBA: Q1 2024 compared with Q2 2024
MeasureQ1 2024Of which not filed for Q2 2024Q2 2024Change
Holders1142103−9
Shares57.0M74.9K56.3M−679.5K (−1.2%)
Value$104.3M$137.1K$57.4M−$46.8M (−44.9%)

2 institutions that held it in Q1 2024 haven't filed for Q2 2024 yet. Not filing isn't selling, so the changes leave them out.

New holders (23)

Institutions that held Akebia Therapeutics, Inc. at the end of Q2 2024 but not at the end of Q1 2024.

Institutions new to AKBA in Q2 2024
InstitutionSharesValue% of portfolio
Nuveen Asset Management, LLC380,535$388.1K0.00%
Corebridge Financial, Inc.111,914$115.3K0.00%
New York State Common Retirement Fund101,100$103.1K0.00%
Alliancebernstein L.P.77,640$79.2K0.00%
Virtu Financial LLC75,079$77.0K0.01%
Voya Investment Management LLC71,697$73.1K0.00%
Private Advisor Group, LLC59,626$60.8K0.00%
MetLife Investment Management54,157$55.2K0.00%
State of Wyoming49,727$50.7K0.01%
National Asset Management, Inc.43,360$44.2K0.00%
SG Americas Securities, LLC33,144$34.0K0.00%
David Loasby20,000$21.6K0.00%
Principal Financial Group Inc21,113$21.5K0.00%
Ameritas Investment Partners, Inc.20,380$20.8K0.00%
Legal & General Group Plc17,967$18.1K0.00%
California State Teachers Retirement System15,073$15.4K0.00%
Xponance, Inc.13,701$14.0K0.00%
Cedrus LLC13,700$14.0K0.01%
Amalgamated Bank7,197$7.00K0.00%
GPS Wealth Strategies Group, LLC3,625$3.70K0.00%
Activest Wealth Management2,000$2.04K0.00%
Redwood Wealth Management Group, LLC300$3060.00%
Laurel Wealth Advisors LLC229$2340.00%

Sold out (32)

Institutions that held Akebia Therapeutics, Inc. at the end of Q1 2024 and filed for Q2 2024 without it.

Institutions that sold out of AKBA in Q2 2024
InstitutionShares, Q1 2024Value, Q1 2024
EAM Investors, LLC428,549$784.2K
Cubist Systematic Strategies, LLC398,247$728.8K
Point72 Asia (Singapore) Pte. Ltd.186,232$340.8K
Y-Intercept (Hong Kong) Ltd140,925$257.9K
ExodusPoint Capital Management, LP137,742$252.0K
DZ BANK AG Deutsche Zentral Genossenschafts Bank, Frankfurt am Main92,554$169.4K
Brevan Howard Capital Management LP81,676$149.5K
Omers Administration Corp77,000$140.9K
Bank of Montreal68,475$126.0K
CTC Alternative Strategies, Ltd.58,700$107.4K
Deerfield Management Company, L.P. (Series C)47,100$86.2K
LMR Partners LLP44,678$81.8K
Lazard Asset Management LLC43,545$79.0K
Jump Financial, LLC41,920$76.7K
Two Sigma Securities, LLC32,073$58.7K
Cannon Global Investment Management, LLC28,000$51.2K
Polymer Capital Management (HK) LTD23,900$43.7K
Jefferies Financial Group Inc.22,500$41.2K
Oxford Asset Management LLP22,262$40.7K
DRW Securities, LLC21,000$38.4K
Group One Trading, L.P.20,678$37.8K
TradeLink Capital LLC13,200$24.0K
Symmetry Investments LP12,400$22.7K
Bayesian Capital Management, LP10,900$19.9K
EntryPoint Capital, LLC10,590$19.4K
Grimes & Company, Inc.10,000$18.3K
Ameritas Advisory Services, LLC12,096$15.7K
Guggenheim Capital LLC1,039$1.90K
Truvestments Capital LLC756$1.38K
NBC Securities, Inc.690$1.00K
Hexagon Capital Partners LLC186$340
Macquarie Group Ltd9,170$17

Not filed for Q2 2024 yet (2)

Institutions that held Akebia Therapeutics, Inc. at the end of Q1 2024 and haven't filed a 13F for Q2 2024. Not filing isn't selling, so they aren't counted as sold out.

Institutions holding AKBA in Q1 2024 that haven't filed for Q2 2024
InstitutionShares, Q1 2024Value, Q1 2024
CWA Asset Management Group, LLC49,000$89.7K
Eudaimonia Partners, LLC25,945$47.5K